LDL goal achievement in chronic coronary heart disease patients: a comparison between usual care and a structures follow-up programme in 766 consecutive patients in cardiology practice
Engelsk titel: LDL goal achievement in chronic coronary heart disease patients: a comparison between usual care and a structures follow-up programme in 766 consecutive patients in cardiology practice
Läs online
Författare:
Heldal, Magnus
;
Pedersen, Terje R
Språk: Eng
Antal referenser: 25
Dokumenttyp:
Översikt
UI-nummer: 17030381
Sammanfattning
Background: The LDL cholesterol (LDL-C) goal achievement in patients with coronary
heart disease (CHD), as recommended by Guidelines, is generally low.
Objective: We sought to compare the outcomes of two different strategies in chronic
CHD patients remitted from general practioners to an out-of-hospital cardiology
practice, one conventional follow-up (CFU) and one structured follow-up
(SFU).
Methods: All 302 consecutive patients with angiographically documented CHD
seen during one year were reviewed and lipid levels after one cardiologist
consultation were collected retrospectively the following year (CFU). During
the two succeeding years, all 464 patients with this diagnosis were followed
prospectively in the cardiology practice in a simple, structured manner until
LDL-C ≤2.0 mmol/L was reached, using more potent statins and with the
addition of ezetimibe if baseline LDL-C was ≥2.5 mmol/L or if a potent statin
did not reduce the LDL-C level to ≤2.0 mmol/L (SFU).
Results: At baseline, only 1/3 of all patients had LDL-C ≤2 mmol/L. After CFU this
increased to 59%, while following the SFU programme 90% reached this
goal. The mean LDL-C levels decreased from 2.4 to 2.2 mmol/L after CFU
and from 2.5 to 1.8 mmol/L in the SFU group, all differences significant at
p<0.001.
Conclusion: A simple structured follow-up programme in out-of-hospital cardiology
practice can bring 90 % of these patients to a LDL-C level of 2.0 mmol/L or
lower, which was the goal at the time of start of this programme, with the use
of more potent statins and the addition of ezetimibe when needed